VEGF、TGF-β1和PD-L1在上皮性卵巢癌组织中的表达及其临床意义

doi:10.16689/j.cnki.cn11-9349/r.2020.03.019

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (1911 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要

目的探讨血管生长因子（VEGF）、转化生长因子β1、程序性死亡因子配体1（PD-L1）在不同卵巢肿瘤组织中的表达情况和三者分别与上皮性卵巢癌临床病理特征之间的关系。方法采用免疫组化法分别检测46例上皮性卵巢癌、20例良性卵巢囊腺瘤及20例正常卵巢中VEGF、TGF-β1及PD-L1的表达情况，并分析其表达与不同临床病理特征之间的相关性。结果免疫组化显示VEGF在上皮性卵巢癌组织、良性卵巢囊腺瘤组织及正常卵巢组织中阳性表达率依次为65.2%（30/46）、25.0%（5/20）、15.0%（3/20）；TGF-β1在上皮性卵巢癌组织、良性卵巢囊腺瘤组织及正常卵巢组织中阳性表达率依次为82.6%（38/46）、30.0%（6/20）、20.0%（4/20）；PD-L1在上皮性卵巢癌组织、良性卵巢囊腺瘤组织及正常卵巢组织中阳性表达率依次为89.1%（41/46）、30.0%（6/20）、25.0%（5/20），VEGF、TGF-β1及PD-L1在上皮性卵巢癌组织中的阳性率均高于良性卵巢囊腺瘤组织和正常卵巢组织，差异有统计学意义（P<0.01）。VEGF、TGF-β1及PD-L1在上皮性卵巢癌组织中的表达均与国际妇产科协会（FIGO）分期及淋巴结转移有关（P<0.05），其中TGF-β1的表达还与CA125升高有关（P<0.05）。在上皮性卵巢癌组织中，VEGF水平与TGF-β1呈正相关（r=0.387，P<0.05）；VEGF与PD-L1呈正相关（r=0.332，P<0.05）；TGF-β1与PD-L1呈正相关（r=0.393，P<0.05）。结论在上皮性卵巢癌组织中VEGF、TGF-β1及PD-L1表达显著增高，三者呈正相关，且均与FIGO分期及淋巴结转移相关，提示VEGF、TGF-β1和PD-L1三者之间可能通过某种机制相互作用，协同促进上皮性卵巢癌的进展，联合检测可能指导上皮性卵巢癌的早诊断早诊治。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	侯建英
	朱巍

关键词 ：卵巢肿瘤｜基因｜血管内皮生长因子｜转化生长因子&beta, 1｜程序性死亡因子配体1

Abstract：Objective To investigate the expressions of VEGF, TGF-β1 and PD-L1 proteins in epithelial ovarian cancer, and to explore the association of the expressions of VEGF, TGF-β1 and PD-L1 with clinicopathological features. Methods Immunohistochemistry was used to detect the expressions of VEGF, TGF-β1 and PD-L1 in 46 cases of epithelial ovarian cancer, 20 cases of benign ovarian cystadenoma and 20 cases of normal ovarian, and analyzing the association of the expressions of VEGF, TGF-β1 and PD-L1 with the clinicopathological features. Results Immunohistochemistry showed that the positive expression rates of VEGF in epithelial ovarian cancer, benign ovarian cystadenoma tissue and normal ovarian tissue were 65.2% (30/46), 25.0% (5/20) and 15.0% (3/20), respectively. The positive expression rates of TGF-β1 in epithelial ovarian cancer, benign ovarian cystadenoma tissue and normal ovarian tissue were 82.6% (38/46), 30.0% (6/20) and 20.0% (4/20), respectively. The positive expression rates of PD-L1 in epithelial ovarian cancer tissues, benign ovarian cystadenoma tissue and normal ovarian tissue were 89.1% (41/46), 30.0% (6/20) and 25.0% (5/20), respectively. The positive rates of VEGF, TGF-β1 and PD-L1 in epithelial ovarian cancer tissues were higher than those in benign and normal ovarian tissues, with statistically significant differences (P<0.01). The expression of VEGF, TGF-β1 and PD-L1 in epithelial ovarian cancer was associated with FIGO staging and lymph node metastasis (P<0.05), and TGF-β1 was also associated with CA125 (P<0.05). In epithelial ovarian cancer,VEGF level was positively correlated with TGF-β1 (r=0.387, P<0.05)；VEGF level was positively correlated with PD-L1 (r=0.332, P<0.05)；TGF-β1 was positively correlated with PD-L1 (r=0.393, P<0.05). Conclusions The expressions of VEGF, TGF-β1 and PD-L1 were significantly up-regulated in epithelial ovarian cancer tissues and the above factors showing a positive correlation. The correlation with FIGO staging and lymph node metastasis suggested that VEGF, TGF-β1 and PD-L1may interact with each other through some mechanism to promote the progress of epithelial ovarian cancer, and the combined detection may guide the early diagnosis and treatment of epithelial ovarian cancer.

Key words： Ovarian neoplasms｜Gene｜Vascular endothelial growth factor｜Transforming growth factor-β1｜Programmed cell death ligand 1

通讯作者: 朱巍，电子邮箱：18686111667@163.com

引用本文:

侯建英，朱巍. VEGF、TGF-β1和PD-L1在上皮性卵巢癌组织中的表达及其临床意义[J]. 肿瘤代谢与营养电子杂志, 2020, 7(3): 352-358.
Hou Jianying,Zhu Wei. Expressions of VEGF, TGF-β1 and PD-L1 in epithelial ovarian cancer and its clinical significance. Electron J Metab Nutr Cancer, 2020, 7(3): 352-358.

1.BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6):394-424.
2.CORTEZ A J, TUDREJ P, KUJAWA K A, et al. Advances in ovarian cancer therapy［J］. Cancer Chemother Pharmacol, 2018, 81(1):17-38.
3.REID B M, PERMUTH J B, SELLERS T A. Epidemiology of ovarian cancer: a review［J］. Cancer Biol Med, 2017, 14(1):9-32.
4.GUAN L Y, LU Y. New developments in molecular targeted therapy of ovarian cancer［J］. Discov Med, 2018, 26(144):219-229.
5.LIU C Z, ZHANG L, CHANG X H, et al. Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer. Chin J Cancer Res, 2012, 24(2):130-137.
6.LI W, JIANG D. Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity［J］.J Pediatr Ophthalmol Strabismus, 2012, 49(4):230-235.
7.YUAN A, YU C J, CHEN W J, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer［J］. Int J Cancer, 2000, 89(6):475-483.
8.LEE J C, CHOW N H, WANG S T, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients ［J］. Eur J Cancer, 2000, 36(6):748-753.
9.MAEDA K, CHUNG Y S, OGAWA Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma ［J］. Cancer, 1996, 77(5):858-863.
10.IKEDA N, ADACHI M, TAKI T, et al. Prognostic significance of angiogenesis in human pancreatic cancer ［J］. Br J Cancer, 1999, 79(9-10):1553-1563.
11.GEORGE DJ, HALABI S, SHEPARD T F, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480［J］. Clin Cancer Res, 2001, 7(7):1932-1936.
12.HATA K, WATANABE Y, NAKAI H, et al. Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy［J］. Anticancer Res, 2011, 31(2):731-737.
13.CHEN W, WAHL S M. TGF-beta: receptors, signaling pathways and autoimmunity［J］. Curr Dir Autoimmun, 2002, 5:62-91.
14.KATSUNO Y, LAMOUILLE S, DERYNCK R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression［J］. Curr Opin Oncol, 2013, 25(1):76-84.
15.Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion［J］. Nat Med, 1999, 12(5):1365-1369.
16.于晓伟, 李春红,张松灵,等.卵巢癌患者PD-L1的表达研究［J］.中国实验诊断学, 2010, 14(11):1854-1856.
17.ZOU W, CHEN L. Inhibitory B7-family molecules in the tumour microenvironment［J］. Nat Rev Immunol, 2008, 8(6):467-477.
18.REID B M, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review［J］. Cancer Biol Med, 2017, 14(1):9-32.
19.GABRILOVICH D I, CHEN H L, GIRGIS K R,et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells［J］.Nat Med, 1996, 2(10):1096-1103.
20.GUO B Q, LU W Q. The prognostic significance of high/positive expression of tissue VEGF in ovarian cancer［J］. Oncotarget, 2018, 9(55):30552-30560.
21.TAKESHITA N, HASEGAWA M, SASAKI K, et al. In vivo expression and regulation of genes associated with vascularization during early response of sutures to tensile force［J］. J Bone Miner Metab, 2017, 35(1):40-51.
22.SHEN W, LI H L, LIU L, et al. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer［J］. Eur Rev Med Pharmacol Sci, 2017, 21(11):2596-2603.
23.LI M O, WAN Y Y, SANJABI S, et al. Transforming growth factor-beta regulation of immune responses［J］. Annu Rev Immunol 2006, 24:99-146.
24.GORDON K J, BLOBE G C. Role of transforming growth factor-beta superfamily signaling pathways in human disease［J］. Biochim Biophys Acta, 2008, 1782(4):197-228.
25.LIU C Z, ZHANG L, CHANG X H, et al. Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer［J］. Chin J Cancer Res, 2012, 24(2):130-137.
26.YAN Z, TIAN X, WANG R, et al. Title Prognosis Significance of ZEB2 and TGF-β1 as well as Other Clinical Characteristics in Epithelial Ovarian Cancer［J］. Int J Gynecol Cancer, 2017, 27(7):1343-1349.
27.BLANK C, GAJEWSKI T F, MACKENSEN A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy［J］. Cancer Immunol Immunother, 2005, 54(4):307-314.
28.薛春燕, 谢荃沁,徐云,等.PD-L1和PD-L2在卵巢癌组织中的表达及对患者预后判断的价值［J］.现代免疫学, 2020, 40(1):1-8.
29.SCHTZ F, STEFANOVIC S, MAYER L, et al. PD-1/PD-L1 pathway in breast cancer［J］. Oncol Res Treat, 2017, 40(5):294-297.
30.WANG L. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study［J］. J Ovarian Res, 2019, 12(1):37.
31.吕萌萌, 沈扬,卢锦,等.PD-1/PD-L1抑制剂在妇科肿瘤中的研究进展［J］.临床肿瘤学杂志, 2019, 24(12):1139-1144.